MTOR and cancer: This is because of up-regulated activity of mTOR (mammalian target of rapamycin) by FKBPs, especially in cells lacking functional PTEN, subverting protein synthesis and tumor growth, The successful treatment of cancer using immunosuppressants FK506 and rapamycin, highlights the potential of targeting FKBPs in cancer therapy.